Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Within- and between-field variability in natural turfgrass and synthetic turf is associated with differences in athlete mechanical loading and perception.

Frontiers in sports and active living·2026
Same author

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Transplantation and cellular therapy·2026
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.

Leukemia·2026
Same author

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: May 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Hiroto Inaba1, David Teachey2, Colleen Annesley3

  • 1St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|February 12, 2025
PubMed
Summary

The NCCN Guidelines offer expert recommendations for treating pediatric acute lymphoblastic leukemia (ALL), focusing on diagnosis and management of T-cell ALL based on current evidence.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Related Experiment Videos

Last Updated: May 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Area of Science:

  • Oncology
  • Pediatric Hematology/Oncology

Background:

  • The National Comprehensive Cancer Network (NCCN) develops evidence-based guidelines for cancer treatment.
  • Pediatric Acute Lymphoblastic Leukemia (ALL) requires specialized treatment protocols.
  • Multidisciplinary expert consensus is crucial for guideline development.

Purpose of the Study:

  • To provide updated recommendations for the diagnosis and management of pediatric T-cell ALL.
  • To outline risk stratification and risk-adapted therapy for pediatric ALL.
  • To detail treatment strategies for various subtypes of pediatric ALL, including BCR::ABL1-positive and -negative B-cell lineage, T-cell lineage, and infant ALL.

Main Methods:

  • Development of guidelines through multidisciplinary expert panel meetings.
  • Review of current evidence to inform treatment recommendations.
  • Focus on risk assessment and stratification for tailored therapy.

Main Results:

  • Comprehensive guidelines covering diagnosis, risk stratification, and treatment of pediatric ALL.
  • Specific recommendations for BCR::ABL1-negative and -positive B-cell lineage, T-cell lineage, and infant ALL.
  • Emphasis on supportive care considerations.

Conclusions:

  • The NCCN Guidelines provide a framework for standardized, evidence-based care for pediatric ALL.
  • This selection highlights key aspects of pediatric T-cell ALL diagnosis and management.
  • Adherence to guidelines aims to optimize treatment outcomes for children with ALL.